HC Wainwright Reiterates “Buy” Rating for Actinium Pharmaceuticals (NYSE:ATNM)

HC Wainwright reiterated their buy rating on shares of Actinium Pharmaceuticals (NYSE:ATNM) in a research note issued to investors on Friday,Benzinga reports. They currently have a $4.00 price target on the stock.

A number of other equities analysts also recently commented on ATNM. StockNews.com downgraded Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. Maxim Group reduced their price objective on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Finally, B. Riley downgraded Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $16.00 to $2.00 in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.40.

Actinium Pharmaceuticals Stock Performance

Shares of ATNM stock opened at $1.42 on Friday. The company has a 50 day moving average of $1.79. Actinium Pharmaceuticals has a 52 week low of $1.33 and a 52 week high of $10.24. The firm has a market capitalization of $44.15 million, a P/E ratio of -1.01 and a beta of 0.14.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC acquired a new stake in Actinium Pharmaceuticals in the second quarter worth approximately $142,000. Bank of New York Mellon Corp increased its holdings in shares of Actinium Pharmaceuticals by 28.3% in the second quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock valued at $639,000 after buying an additional 19,035 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Actinium Pharmaceuticals by 6.0% in the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock valued at $11,325,000 after buying an additional 82,113 shares in the last quarter. The Manufacturers Life Insurance Company bought a new position in shares of Actinium Pharmaceuticals in the second quarter valued at $92,000. Finally, Marshall Wace LLP increased its holdings in shares of Actinium Pharmaceuticals by 67.9% in the second quarter. Marshall Wace LLP now owns 256,026 shares of the company’s stock valued at $1,895,000 after buying an additional 103,557 shares in the last quarter. 27.50% of the stock is currently owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).